Havana, Dec 31 (Prensa Latina) In light of a slight increase in Covid-19 cases in Cuba, the Ministry of Public Health (MINSAP) decided to administer Nasalferon to at-risk groups.
“Nasalferon, an antiviral, immunomodulatory, and prophylactic drug for nasal administration, will be used in at-risk groups in Cuba to prevent Covid-19 contagions and to prevent patients from contracting severe forms of the disease,” the Havana-based Genetic Engineering and Biotechnology Center (CIGB) reported on its Twitter account.
The drug, developed by the CIGB and used to fight Covid-19, could be administered against several acute respiratory diseases.
The medicine is a formulation of the nasal Alfa-2b-human recombinant Interferon, whose immunomodulatory and antiviral properties prevent the replication of the SARS-CoV-2 coronavirus, which causes Covid-19, and strengthen the immune system.
After its safety was proven, Nasalferon played a leading role when the Delta strain of the novel coronavirus broke out in the country, and it was necessary to increase the population’s immune response.